Company Focus
Moderna
Latest Moderna News
Biotechnology
Moderna has reported third-quarter 2024 revenues of $1.9 billion, marking a slight increase from the $1.8 billion posted in the same period in 2023. 7 November 2024
Related News
Insights
Company Spotlight
A biopharma company developing products for the treatment of human disease, including immunology, metabolism, cardiology and ophthalmology.
Latest News & Features of interest to Moderna
Pharmaceutical
Germany’s Bayer has reported group revenue of 11.1 billion euros ($12.2 billion) in the second quarter of 2024, ahead of the 10.9 billion euros average of analysts’ estimates and up by 1% on the same period a year ago. 6 August 2024
Biotechnology
Biotech incubators Two River and Third Rock Ventures have launched TRC 2004, a new company focusing on bispecific T-cell engagers (BiTE), according to a filing with the Hong Kong Stock Exchange. 6 August 2024
Biotechnology
Agenus has revealed via a Securities and Exchange Commission (SEC) filing that US pharma major Bristol Myers Squibb (NYSE: BMS) was pulling out of a licensing deal. 5 August 2024
Biotechnology
US immune-oncology firm iTeos Therapeutics today announced the appointment of David Feltquate as chief medical officer (CMO). 5 August 2024
Biotechnology
Californian firm Anivive Lifesciences is broadening its scope from animal health to human vaccines with a significant new funding grant. 5 August 2024
Pharmaceutical
Germany’s Bayer has announced today that a key trial—FINEARTS-HF—has met its primary endpoint. 5 August 2024
Pharmaceutical
US rare disease drug focussed company Zevra Therapeutics saw its shares rise nearly 43% to $9.00 in after-hours trading on Friday as it announced a positive development for its arimoclomol. 5 August 2024
Biotechnology
Clinical trial results featured heavily in the news last week, first with Dutch biotech NewAmsterdam releasing data on its hypercholesterolemia candidate obicetrapib. US drug developer MacroGenics announced receipt of a $100 million milestone from Incyte relating to progress in its deal on Zynyz and updated on the development of prostate cancer drug vobra duo. Germany’s BioNTech announced top-line Phase II results of its mRNA cancer immunotherapy BNT111. Also, US pharma major Eli Lilly released new data on its GLP-1 drug tirzepatide – already marketed for diabetes and obesity under the trade names Mounjaro and Zepbound, respectively - in heart failure. 4 August 2024
Pharmaceutical
Pharma giants are vehemently opposing the Indian government's proposal to apply the trade margin rationalization (TMR) formula to certain drugs with the aim of reducing drug prices. 2 August 2024
Biotechnology
Dallas, Texas-based Instil Bio and China’s ImmuneOnco Biopharmaceuticals have announced a license and collaboration agreement. 2 August 2024
Latest In Brief for Moderna
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Latest Relevant Ones To Watch News
California, USA-based biotech Nektar Therapeutics’ shares closed up more than 8% at $1.33 yesterday after it announced the sale of its only manufacturing facility. 5 November 2024
18 October 2024
24 September 2024
23 September 2024
16 September 2024
23 August 2024
22 August 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze